Online Exclusives

Online Exclusives

In 2016, FDA Drug Approvals Hit a Six-Year Low

The U.S. Food and Drug Administration (FDA) approved 22 medications in 2016, which was the lowest number of FDA approvals in a single year...

Commonwealth Fund Study Finds Most Mobile Health Apps Are Too Complicated for Patients

Though health applications are designed to help patients manage chronic conditions, many can present challenges to the vulnerable populations who are most likely to...

FDA Grants Investigational New Drug Approval for CAR T-Cell Therapy

The U.S. Food and Drug Administration (FDA) approved an Investigational New Drug Application for UCART123, a gene-edited chimeric antigen receptor (CAR) T-cell therapy targeting...

FDA Grants Orphan Drug Designation for SB-FIX for Hemophilia B

The U.S. Food and Drug Administration granted orphan drug designation to SB-FIX – a zinc finger nuclease–mediated in vivo genome-editing product – for patients...

Outpatient Treatment of Pulmonary Embolism Reduces Rates of Adverse Events

The decision to hospitalize patients with acute pulmonary embolism (PE) or treat them as outpatients remains controversial, but according to a study published in...

Older Patients With DLBCL Treated With Immunochemotherapy Have Significant Treatment-Related Morbidity and Mortality Risk

One in 45 older patients treated with immunochemotherapy for diffuse large B-cell lymphoma (DLBCL) die during the first month of treatment, and 25 percent...

Genetics Help Explain Why Cancer Affects Men and Women Differently

An analysis of data from 3,200 male and female patients with 13 cancer types enrolled in the Cancer Genome Atlas database reveals that molecular...

European Commission Approves Injectable Rituximab for Chronic Lymphocytic Leukemia

The European Commission approved subcutaneous rituximab for the treatment of previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). The approval was based the results of...

Global Patient Registry Launched for Castleman Disease

ACCELERATE (Accelerating Castleman Care with Electronic Longitudinal registry, E-Repository, And Treatment Effectiveness research), a patient-driven natural history registry for patients with Castleman disease, was...

Europe’s CHMP Recommends Rituximab Biosimilar Approval

Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for a biosimilar version of rituximab for the treatment of non-Hodgkin lymphoma (NHL)...
Advertisement

Current Issue

September 2019 Volume 5 Issue 11

September 2019, Volume 5, Issue 11

This issue explores politics in the exam room, demystifies proteomic analysis in hematology, and more.